Relmada Therapeutics, Inc.
RLMD
$4.80
$0.051.05%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -61.93M | -58.88M | -57.39M | -56.17M | -67.81M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 14.48M | 15.47M | 15.55M | 18.26M | 22.19M |
| Change in Net Operating Assets | 1.45M | 621.00K | -3.95M | -2.08M | -4.31M |
| Cash from Operations | -45.99M | -42.79M | -45.79M | -39.99M | -49.92M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -187.82M | -198.73M | -48.14M | 40.14M | 49.53M |
| Cash from Investing | -187.82M | -198.73M | -48.14M | 40.14M | 49.53M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 253.74M | 253.64M | 93.64M | 0.00 | 0.00 |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -9.95M | -3.50M | -73.00K | -245.50K | -335.10K |
| Cash from Financing | 243.79M | 250.14M | 93.56M | -245.50K | -335.10K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 9.98M | 8.63M | -360.50K | -99.40K | -733.00K |